The success of early CAR-T cell therapies was partly luck. Future therapies face a high bar, as an ideal target must meet three criteria: 1) be abundant on cancer cells, 2) be indispensable for the cancer's survival, and 3) be dispensable for the patient's healthy tissues to avoid lethal toxicity.

K-36's epigenetic drug focuses on reversing the malignant programming of cancer cells. This approach aims to resensitize tumors to other treatments, making combination therapies the core strategy for achieving more durable responses, rather than relying on monotherapy to kill cells directly.

Step Pharma's synthetic lethality approach targets two redundant enzymes in the same pathway. Deleting one makes cancer cells entirely dependent on the other. This direct dependency is harder for biology to circumvent compared to approaches targeting different, interconnected pathways, creating a "cleaner" kill mechanism.

By simultaneously targeting dozens of functionally unrelated survival genes across different chromosomes, Nuago's therapy makes it statistically improbable for cancer cells to mutate and develop escape routes. This multi-pronged attack from a single drug construct is a core advantage over therapies that cancer can evolve around.

CEO Dan Schmitt outlines a three-part test for a new drug: it must effectively engage its intended biological target, avoid interacting with other enzymes to prevent toxicity, and be deliverable to a patient in sufficient quantities to be effective. This framework simplifies the core challenges of drug development.

Instead of creating therapies for hundreds of specific driver mutations, which vary widely between patients, Earli's platform targets downstream commonalities—the "hallmarks of cancer" like rapid cell proliferation. These pathways are where diverse mutations converge, creating a more universal and reliable target across different cancers.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

The therapy’s targets are fundamental survival genes conserved from worms to humans. This deep biological foundation makes the treatment 'cancer-agnostic,' effective regardless of tumor origin, subtype, or the patient's genetic background. The company has successfully killed 66 different tumor types across seven species.

K-36's strategy starts with multiple myeloma patients having the T414 translocation, a small, well-defined group where the drug's biological mechanism is strongest. This approach aims to secure a clear clinical proof-of-concept before expanding to broader, biomarker-defined populations, thus de-risking development.